Investor sentiment has fundamentally changed. During the COVID era, investors funded good ideas. Now, they want to de-risk their investments as much as possible, often requiring solid Phase 1 and even compelling Phase 2 data before committing significant capital.

The most common investor misconception is that cancer vaccines have "never worked." The key rebuttal is that past failures targeted generic, shared antigens. The new generation of vaccines is fundamentally different, targeting specific mutations unique to each patient's tumor, which changes the entire paradigm.

The initial hope for a revolution across many immune checkpoints has faded. With most targets outside of PD-1 failing to deliver, investors and pharma have grown fatigued. This disappointment has accelerated the industry's pivot towards other modalities like ADCs and cell therapies.

In a tight funding environment, a significant portion of startups now secure pharma partnerships *before* their Series A. This pre-validation has become a major draw for VCs, signaling a shift where corporate buy-in is needed to de-risk early-stage science for investors.

Even though companies like Moderna (mRNA) and Transgene (viral vector) use different platforms, positive results from any of them help validate the entire individualized neoantigen approach for investors and clinicians. The massive unmet medical need ensures the market is large enough to support multiple successful players.

Despite big pharma's focus on scalable RNA technologies, Series A funding shows a surprising resurgence in investment for cell and gene therapy. This suggests early-stage VCs see significant unsolved value in areas like targeted delivery and gene editing, bucking the broader clinical and commercial narrative.

Market dynamics, like investor fixation on AI or predatory short-selling, pose a greater risk to biotech firms than clinical trial results. A company can have a breakthrough drug but still fail if its stock—its funding currency—is ignored or attacked by Wall Street.

A profound capital shift has occurred where both venture investors and large pharma partners focus on clinically validated assets. This moves investment away from riskier, early-stage science, creating a significant funding gap for foundational research and pre-clinical startups.

Venture capital for US seed and Series A cell and gene therapy companies has collapsed from a historical high of 17-21% of deals to only 7% this year. The sharp decline is driven by a confluence of factors including patient deaths, persistent manufacturing challenges, and growing regulatory uncertainty.